Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction.

Jackson, Alice; Jhund, Pardeep; Anand, Inder; Düngen, Hans-Dirk; Lam, Carolyn; Lefkowitz, Marty; Linssen, Gerard; Lund, Lars; Maggioni, Aldo; Pfeffer, Marc; Rouleau, Jean; Saraiva, Jose; Senni, Michele; Vardeny, Orly; Wijkman, Magnus; Yilmaz, MEHMET; Saito, Yoshihiko; Zile, Michael; Solomon, Scott; Mcmurray, John

doi:10.1093/eurheartj/ehab499

Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction.

Atıf İçin Kopyala

Jackson A. M., Jhund P. S., Anand I. S., Düngen H., Lam C. S. P., Lefkowitz M. P., ...Daha Fazla

European heart journal, cilt.42, sa.36, ss.3741-3752, 2021 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 42 Sayı: 36
Basım Tarihi: 2021
Doi Numarası: 10.1093/eurheartj/ehab499
Dergi Adı: European heart journal
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database
Sayfa Sayıları: ss.3741-3752
Anahtar Kelimeler: Heart failure, Preserved ejection fraction, Sacubitril-valsartan, Blood pressure, DOUBLE-BLIND, BLOOD-PRESSURE, RECEPTOR, NEPRILYSIN, SPIRONOLACTONE, INHIBITOR, LCZ696, DOXAZOSIN, PLACEBO
Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Aims Patients with heart failure and preserved ejection fraction (HFpEF) frequently have difficult-to-control hypertension. We examined the effect of neprilysin inhibition on 'apparent resistant hypertension' in patients with HFpEF in the PARAGON-HF trial, which compared the effect of sacubitril-valsartan with valsartan.